Cancer drug doubles survival in pancreatic cases

What's happened

New results from ASCO show daraxonrasib nearly doubles median survival for pancreatic cancer, signaling a potential shift in how Ras-mutant cancers are treated. Trials also highlight progress against head and neck cancers and bladder cancer with immunotherapy and targeted therapies.

What's behind the headline?

Key takeaways

This round of ASCO findings shows that progress in cancer treatment comes from incremental, targeted advances rather than a single breakthrough.
Daraxonrasib operates by targeting Ras family mutations, opening options for up to ~40% of colorectal cancers and ~30% of small-cell lung cancers where Ras plays a role.
Routine genetic screening is expanding the pool of patients who can benefit from such drugs, potentially broadening their impact across cancer types.

What this means for patients

For pancreatic cancer, survival has historically been poor; a median gain of about 7 months could substantially affect quality and length of life for some patients.
The field is moving toward personalized medicine, where treatment is aligned with specific genetic profiles rather than cancer type alone.

How we got here

The Guardian reports breakthroughs from the ASCO meeting in Chicago, including a jab for head and neck cancers, an immunotherapy for bladder cancer, and the Ras-targeting drug daraxonrasib. This builds on decades of cancer research, including the recognition of Ras as a druggable target after years of being deemed undruggable.

Our analysis

The Guardian (The Guardian), ASCO conference summaries; supporting context from cancer research community.

Go deeper

What does this mean for access to genetic testing?
Will these advances translate into immediate changes in standard care?
Which cancers are next likely to benefit from Ras-targeted therapies?